Under the agreement, Endo shareholders are slated to receive a total of $80 million in cash and own 49.9% of the combined company, while Mallinckrodt shareholders will have a 50.1% piece of the pie.

Mallinckrodt and Endo, pharmaceutical companies that have each encountered business struggles, announced Thursday a $6.7 billion merger that they contend will result in a combined entity with the ...

Find Out More about the Bolton-Brush Growth Study Center. The Oral and Maxillofacial Radiology Clinic offers 3D imaging of the head and neck using the latest Cone Beam Computed Tomography (CBCT) ...